MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2

Decera Clinical Education Oncology Podcast · Aug 28, 2020 · 15m

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCLC with topics including:

Whether testing for MET exon 14 status should be standard of care

Parallel vs sequential testing by DNA-based vs RNA-based NGS

Co-occurring driver mutations in patients with METex14 mutation–positive NSCLC

Optimal use of immune checkpoint inhibitor–based therapy in the setting of METex14-positive disease, including sequencing with MET inhibitor–based therapy

EMA regulatory…